Vaccine Strategy in Melanoma

Minyoung Kwak; Katie M Leick; Marit M Melssen; Craig L Slingluff Jr

doi:10.1016/j.soc.2019.02.003

Vaccine Strategy in Melanoma

Surg Oncol Clin N Am. 2019 Jul;28(3):337-351. doi: 10.1016/j.soc.2019.02.003. Epub 2019 Apr 15.

Authors

Minyoung Kwak¹, Katie M Leick², Marit M Melssen³, Craig L Slingluff Jr⁴

Affiliations

¹ Division of Surgical Oncology, Department of Surgery, University of Virginia, PO Box 800709, Charlottesville, VA 22908-0709, USA; Department of Surgery, SUNY Downstate, Brooklyn, NY, USA; Carter Immunology Center, University of Virginia, Charlottesville, VA, USA.
² Division of Surgical Oncology, Department of Surgery, University of Virginia, PO Box 800709, Charlottesville, VA 22908-0709, USA; Carter Immunology Center, University of Virginia, Charlottesville, VA, USA; Department of Surgery, University of Iowa, Iowa City, IA, USA.
³ Division of Surgical Oncology, Department of Surgery, University of Virginia, PO Box 800709, Charlottesville, VA 22908-0709, USA; Department of Microbiology, Immunology, and Cancer Biology, University of Virginia, Charlottesville, VA, USA; Department of Immunohematology and Blood Transfusion, Leiden University Medical Center, Leiden, the Netherlands.
⁴ Division of Surgical Oncology, Department of Surgery, University of Virginia, PO Box 800709, Charlottesville, VA 22908-0709, USA; Carter Immunology Center, University of Virginia, Charlottesville, VA, USA. Electronic address: [email protected].

Abstract

The incidence of melanoma continues to increase even as advances in immunotherapy have led to survival benefits in advanced stages. Vaccines are capable of inducing strong, antitumor immune responses with limited toxicity. Some vaccines have demonstrated clinical benefit in clinical trials alone; however, others have not despite inducing strong immune responses. Recent advancements have improved vaccine design, and combining vaccines with other immunotherapies offers promise. This review highlights the underlying principles of vaccine development, common components of vaccines, and the remaining challenges and future directions of vaccine therapy in melanoma.

Keywords: Melanoma; Neoantigen; T cell; Tumor-associated antigen; Vaccine; Vaccine adjuvant.

Publication types

Research Support, N.I.H., Extramural
Research Support, Non-U.S. Gov't
Review

MeSH terms

Animals
Antigens, Neoplasm / immunology*
Cancer Vaccines / therapeutic use*
Humans
Immunotherapy / methods*
Melanoma / immunology
Melanoma / therapy*

Substances

Antigens, Neoplasm
Cancer Vaccines

Abstract

Publication types

MeSH terms

Substances

Grants and funding